BioCentury | Oct 13, 2017
Financial News

Intezyne raises $10M in series A

On Oct. 6, Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO...
BioCentury | Oct 6, 2017
Financial News

Intezyne raises $10M series A

Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO E. Russell McAllister...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BioCentury | Dec 1, 2016
Financial News

Axial Biotherapeutics completes venture financing

Axial raised $19.2 million in a series A round led by Longwood Fund and Domain Associates. Kairos Ventures, Heritage Medical Systems and high net worth investors also participated. Axial Biotherapeutics Inc. , Boston, Mass. Alicia Parker...
BioCentury | Aug 8, 2016
Financial News

Ortho Regenerative Technologies completes private placement of units

Ortho Regenerative Technologies Inc. (CNSX:ORH), Kirkland, Quebec Business: Musculoskeletal Date completed: 2016-08-03 Type: Private placement of units Raised: C$460,000 ($352,406) Units: 920,000 Price: C$0.50 (unit) Shares after offering: 14.9 million Investor: High net worth investors...
BioCentury | Jan 18, 2016
Financial News

Cardiorentis completes venture financing

Cardiorentis AG , Zug, Switzerland Business: Cardiovascular Date completed: 2016-01-11 Type: Venture financing Raised: CHF60 million ($60.1 million) Investor: High net worth investors WIR Staff Cardiovascular...
BioCentury | Nov 9, 2015
Financial News

OncoVista completes bridge financing

...Type: Bridge financing Raised: Not disclosed Shares outstanding prior: 22 million Investors: Chicago Venture Partners; high net worth investor...
BioCentury | Jul 20, 2015
Financial News

Courtagen Life Sciences completes venture financing

Courtagen Life Sciences Inc. , Woburn, Mass. Business: Proteomics, Genomics Date completed: 2015-07-15 Type: Venture financing Raised: $20 million Investors: Harbor Light Capital Partners; Adler; Bunker Hill Capital; First Analysis; high net worth investors WIR Staff...
BioCentury | Apr 1, 2013
Financial News

Prana completes private placement

Prana Biotechnology Ltd. (ASX:PBT; NASDAQ:PRAN), Melbourne, Australia Business: Neurology Date completed: 3/27/13 Type: Private placement Raised: A$7 million ($7.3 million) Shares: 35.9 million Price: A$0.20 Shares after offering: 380 million Underwriter: JM Financial Group Investors:...
BioCentury | Aug 29, 2011
Finance

SK's new thing

SK's new thing Branching out from its high-net worth investor base, SK Capital Partners tapped institutional investors for $500 million to close out its third fund. The private equity firm also is adding healthcare to...
Items per page:
1 - 10 of 10
BioCentury | Oct 13, 2017
Financial News

Intezyne raises $10M in series A

On Oct. 6, Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO...
BioCentury | Oct 6, 2017
Financial News

Intezyne raises $10M series A

Intezyne Technologies Inc. (Tampa, Fla.) raised $10 million in an oversubscribed series A round led by existing investor Gaston Capital Healthcare Fund (GCHF). Undisclosed high-net-worth investors and family offices also participated. CFO E. Russell McAllister...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
BioCentury | Dec 1, 2016
Financial News

Axial Biotherapeutics completes venture financing

Axial raised $19.2 million in a series A round led by Longwood Fund and Domain Associates. Kairos Ventures, Heritage Medical Systems and high net worth investors also participated. Axial Biotherapeutics Inc. , Boston, Mass. Alicia Parker...
BioCentury | Aug 8, 2016
Financial News

Ortho Regenerative Technologies completes private placement of units

Ortho Regenerative Technologies Inc. (CNSX:ORH), Kirkland, Quebec Business: Musculoskeletal Date completed: 2016-08-03 Type: Private placement of units Raised: C$460,000 ($352,406) Units: 920,000 Price: C$0.50 (unit) Shares after offering: 14.9 million Investor: High net worth investors...
BioCentury | Jan 18, 2016
Financial News

Cardiorentis completes venture financing

Cardiorentis AG , Zug, Switzerland Business: Cardiovascular Date completed: 2016-01-11 Type: Venture financing Raised: CHF60 million ($60.1 million) Investor: High net worth investors WIR Staff Cardiovascular...
BioCentury | Nov 9, 2015
Financial News

OncoVista completes bridge financing

...Type: Bridge financing Raised: Not disclosed Shares outstanding prior: 22 million Investors: Chicago Venture Partners; high net worth investor...
BioCentury | Jul 20, 2015
Financial News

Courtagen Life Sciences completes venture financing

Courtagen Life Sciences Inc. , Woburn, Mass. Business: Proteomics, Genomics Date completed: 2015-07-15 Type: Venture financing Raised: $20 million Investors: Harbor Light Capital Partners; Adler; Bunker Hill Capital; First Analysis; high net worth investors WIR Staff...
BioCentury | Apr 1, 2013
Financial News

Prana completes private placement

Prana Biotechnology Ltd. (ASX:PBT; NASDAQ:PRAN), Melbourne, Australia Business: Neurology Date completed: 3/27/13 Type: Private placement Raised: A$7 million ($7.3 million) Shares: 35.9 million Price: A$0.20 Shares after offering: 380 million Underwriter: JM Financial Group Investors:...
BioCentury | Aug 29, 2011
Finance

SK's new thing

SK's new thing Branching out from its high-net worth investor base, SK Capital Partners tapped institutional investors for $500 million to close out its third fund. The private equity firm also is adding healthcare to...
Items per page:
1 - 10 of 10